Loading...
Thumbnail Image
Item

Quantifying evidence for phenotypic specificity (PP4) for syndromic phenotypes: large-scale integration of rare germline FH variants from diagnostic laboratory testing for HLRCC and renal cancer

Allen, S.
Rowlands, C. F.
Butler, S.
Durkie, M.
Horton, C.
Pesaran, T.
Richardson, M.
Robinson, R.
Garrett, A.
Burghel, G. J.
... show 10 more
Citations
Google Scholar:
Altmetric:
Abstract
PURPOSE: Hereditary leiomyomatosis and renal cell cancer (HLRCC) is a rare cancer susceptibility syndrome exclusively attributable to pathogenic variants in FH (HGNC:3700). This article quantitatively weights the phenotypic context (PP4/PS4) of such very rare variants in FH. METHODS: We collated clinical diagnostic testing data on germline FH variants from 387 individuals with HLRCC and 1780 individuals with renal cancer and compared the frequency of 'very-rare' variants in each phenotypic cohort with 562,295 population controls. We generated pan-gene very rare variant likelihood ratios (PG-VRV-LRs), domain-specific likelihood ratios for missense variants (DS-VRMV-LR) using spatial clustering analysis, and log(2.08) likelihood ratios (LLRs) as applicable within the updated American College of Medical Genetics and Genomics/Association for Molecular Pathology variant classification framework. RESULTS: For HLRCC, the PG-VRV-LR was estimated to be 2669.4 (95% CI 1843.4-3881.2, LLR 10.77) for truncating variants and 214.7 (95% CI 185.0-246.9, LLR 7.33) for missense variants. For renal cancer, the PG-VRV-LR was 95.5 (95% CI 48.9-183.0, LLR 6.23) for truncating variants and 5.8 (95% CI 3.5-9.3, LLR 2.39) for missense variants. Clustering analysis in HLRCC cases revealed 3 'hotspot' regions wherein the DS-VRMV-LR increased to 1226.9. CONCLUSION: These data provide quantitative measures for very rare missense and truncating variants in FH, which reflect the differing phenotypic specificity of HLRCC and renal cancer and may be applicable in clinical variant classification.
Affiliation
Division of Genetics and Epidemiology, The Institute of Cancer Research, London, United Kingdom. Central and South Genomic Laboratory Hub, Birmingham Women's and Children's NHS Foundation Trust, Birmingham, United Kingdom. North East and Yorkshire Genomic Laboratory Hub, Sheffield Children's NHS Foundation Trust, Sheffield, United Kingdom. Ambry Genetics, Aliso Viejo, CA. Yorkshire Regional Genetics Service, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom. Division of Genetics and Epidemiology, The Institute of Cancer Research, London, United Kingdom; St George's University Hospitals NHS Foundation Trust, Tooting, London, United Kingdom. Manchester Centre for Genomic Medicine and NW Laboratory Genetics Hub, Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom; Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine, and Health, The University of Manchester, Manchester, United Kingdom. Central and South Genomics Laboratory Hub, Wessex Genomics Laboratory Service, University Hospital Southampton NHS Foundation Trust, Salisbury, United Kingdom. Genomics and Molecular Medicine Service, Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom. St George's University Hospitals NHS Foundation Trust, Tooting, London, United Kingdom. Institute of Medical Genetics, University Hospital of Wales, Cardiff and Vale University Health Board, Cardiff, United Kingdom. Laboratory Genetics, Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde, Glasgow, United Kingdom. South East Scotland Clinical Genetics, Western General Hospital, Edinburgh, United Kingdom. Department of Clinical Genetics, CHI at Crumlin, Dublin, Ireland. Clinical Genetics Department, St George's University Hospitals NHS Foundation Trust, St George's University of London, Blackshaw Rd, London, United Kingdom; City St George's, University of London, Tooting Campus, Cranmer Terrace, London, United Kingdom. Aston Medical School, College of Health and Life Sciences, Aston University, Birmingham, United Kingdom; Department of Genomic Medicine, University of Cambridge, Cambridge, United Kingdom. Peninsula Regional Genetics Service, Royal Devon University Healthcare NHS Foundation Trust, Exeter, United Kingdom; Department of Clinical and Biomedical Sciences, University of Exeter Medical School, Exeter, United Kingdom. The Royal Marsden NHS Foundation Trust, Fulham Road, London, United Kingdom. Division of Genetics and Epidemiology, The Institute of Cancer Research, London, United Kingdom; The Royal Marsden NHS Foundation Trust, Fulham Road, London, United Kingdom. Electronic address: turnbull.lab@icr.ac.uk.
Description
Date
2025
Publisher
Keywords
Type
Article
Citation
Allen S, Rowlands CF, Butler S, Durkie M, Horton C, Pesaran T, et al. Quantifying evidence for phenotypic specificity (PP4) for syndromic phenotypes: Large-scale integration of rare germline FH variants from diagnostic laboratory testing for HLRCC and renal cancer. Genetics in medicine : official journal of the American College of Medical Genetics. 2025 Sep 4;27(11):101565. PubMed PMID: 40916913. Epub 2025/09/08. eng.
Journal Title
Journal ISSN
Volume Title
Embedded videos